5. Bibliografía

-Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014; 90:229-35.

-Salah LA, Faergemann J. A retrospective analysis of skin bacterial colonisation, susceptibility and resistance in atopic dermatitis and impetigo patients. Acta Derm Venereol. 2015; 95:532-5.

-Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, Tuicakau M, Koroi A, Ritova R, Andrews R, Kaldor JM, Steer AC. The Epidemiology of Scabies and Impetigo in Relation to Demographic and Residential Characteristics: Baseline Findings from the Skin Health Intervention Fiji Trial. Am J Trop Med Hyg. 2017; 97:845-850.

-Nakaminami H, Sugiyama T, Okamura Y, Hanawa M, Abou M, Sawada K, Chiba Y, Kobayashi Y, Kawasaki S, Ueki T, Funatsu S, Nagatani T, Noguchi N. Comparative analysis of methicillin-resistant Staphylococcus aureus isolated from outpatients of dermatology unit in hospitals and clinics. J Infect Chemother. 2018. pii: S1341-321X(18)30288-5.

-Edge R, Argáez C. Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Feb. CADTH Rapid Response Reports.

-Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF; DMID 07-0051 Team. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015; 372:1093-103.

-Tanus T, Scangarella-Oman NE, Dalessandro M, Li G, Breton JJ, Tomayko JF. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus. Adv Skin Wound Care. 2014; 27:548-59.

-Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, Hebert AA. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154:806-813.

-Laureano AC, Schwartz RA, Cohen PJ. Facial bacterial infections: folliculitis. Clin Dermatol. 2014; 32:711-4.

-Khanna N, Chandramohan K, Khaitan BK, Singh MK. Post waxing folliculitis: a clinicopathological evaluation. Int J Dermatol. 2014; 53:849-54.

-Morand A, Morand JJ. Pseudomonas aeruginosa en dermatologie. Ann Dermatol Venereol. 2017; 144:666-675.

-Prindaville B, Belazarian L, Levin NA, Wiss K. Pityrosporum folliculitis: A retrospective review of 110 cases. J Am Acad Dermatol. 2018; 78:511-514.

-Ibler KS, Kromann CB. Recurrent furunculosis – challenges and management: a review. Clin Cosmet Investig Dermatol. 2014; 7:59-64.

-El-Gilany AH, Fathy H. Risk factors of recurrent furunculosis. Dermatol Online J. 2009; 15:16.

-Shallcross LJ, Hayward AC, Johnson AM, Petersen I. Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care. Br J Gen Pract. 2015; 65:e668-76.

-Pürnak S, Durdu M, Tekindal MA, Güleç AT, Seçkin D. The prevalence of Malassezia folliculitis in patients with papulopustular/comedonal acne, and their response to antifungal treatment. Skinmed. 2018; 16:99-104.

-Teraki Y, Nakamura K. Rubbing skin with nylon towels as a major cause of pseudomonas folliculitis in a Japanese population. J Dermatol. 2015; 42:81-3.

-Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59:e10-52.

-Morris AD. Cellulitis and erysipelas. BMJ Clin Evid. 2008 Jan 2;2008.

-Bläckberg A, Trell K, Rasmussen M. Erysipelas, a large retrospective study of aetiology and clinical presentation. BMC Infect Dis. 2015;15:402.

-Inghammar M, Rasmussen M, Linder A. Recurrent erysipelas–risk factors and clinical presentation. BMC Infect Dis. 2014; 14:270.

-Gunderson CG, Cherry BM, Fisher A. Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with Cellulitis. J Gen Intern Med. 2018; 33:1553-1560.

-Chlebicki MP, Oh CC. Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment. Curr Infect Dis Rep. 2014; 16:422.-Cannon J, Rajakaruna G, Dyer J, Carapetis J, Manning L. Severe lower limb cellulitis: defining the epidemiology and risk factors for primary episodes in a population-based case-control study. Clin Microbiol Infect. 2018; 24:1089-1094.

-Blumberg G, Long B, Koyfman A. Clinical Mimics: An Emergency Medicine-Focused Review of Cellulitis Mimics. J Emerg Med. 2017; 53:475-484.

-Griffith ME, Ellis MW. Antimicrobial activity against CA-MRSA and treatment of uncomplicated nonpurulent cellulitis. Expert Rev Anti Infect Ther. 2013; 11:777-80.

-Oh CC, Ko HC, Lee HY, Safdar N, Maki DG, Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. J Infect. 2014; 69:26-34.

-Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD004299.

-Inci M, Serarslan G, Ozer B, Inan MU, Evirgen O, Erkaslan Alagoz G, Duran N. The prevalence of interdigital erythrasma in southern region of Turkey. J Eur Acad Dermatol Venereol. 2012; 26:1372-6.

-Badri T, Sliti N, Benmously R, Hammami H, Ben Jennet S, Mokhtar I, Fenniche S. L’érythrasma: étude de 16 cas. Tunis Med. 2014; 92:245-8.

-Polat M, Ilhan MN. The prevalence of interdigital erythrasma: a prospective study from an outpatient clinic in Turkey. J Am Podiatr Med Assoc. 2015; 105:121-4.

-Greywal T, Cohen PR. Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy. Dermatol Online J. 2017; 23. pii: 13030/qt9zh116s1.

-Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat. 2013; 24:70-4.

-de Almeida HL Jr, Siqueira RN, Meireles Rda S, Rampon G, de Castro LA, Silva RM. Pitted keratolysis. An Bras Dermatol. 2016; 91:106-8

-Kaptanoglu AF, Yuksel O, Ozyurt S. Plantar pitted keratolysis: a study from non-risk groups. Dermatol Reports. 2012; 4:e4.

-Greywal T, Cohen PR. Pitted keratolysis: successful management with mupirocin 2% ointment monotherapy. Dermatol Online J. 2015; 21. pii: 13030/qt6155v9wk.

-Bristow IR, Lee YL. Pitted keratolysis: a clinical review. J Am Podiatr Med Assoc. 2014; 104:177-82.

-Mouffok N, Parola P, Lepidi H, Raoult D. Mediterranean spotted fever in Algeria -new trends. Int J Infect Dis. 2009; 13:227-35.

-Colomba C, Trizzino M, Giammanco A, Bonura C, Di Bona D, Tolomeo M, Cascio A. Israeli Spotted Fever in Sicily. Description of two cases and minireview. Int J Infect Dis. 2017; 61:7-12.

-Amaro M, Bacellar F, França A. Report of eight cases of fatal and severe Mediterranean spotted fever in Portugal. Ann N Y Acad Sci. 2003; 990:331-43.

-Crespo P, Seixas D, Marques N, Oliveira J, da Cunha S, Meliço-Silvestre A.Mediterranean spotted fever: case series of 24 years (1989-2012). Springerplus. 2015; 4:272.

-García-Magallón B, Cuenca-Torres M, Gimeno-Vilarrasa F, Guerrero-Espejo A. Fiebre botonosa mediterránea: epidemiología en España durante el periodo 2009-2012.. Rev Esp Salud Publica. 2015; 89:321-8.

-Espejo E, Andrés M, Garcia MC, Fajardo A, Mauri M, Pérez J, Bella F. Mediterranean spotted fever in the elderly: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2019. doi:10.1007/s10096-019-03558-3.

-Papa A, Dalla V, Petala A, Maltezou HC, Maltezos E. Fatal Mediterranean spotted fever in Greece. Clin Microbiol Infect. 2010; 16:589-92.

-Kuloglu F, Rolain JM, Akata F, Eroglu C, Celik AD, Parola P. Mediterranean spotted fever in the Trakya region of Turkey. Ticks Tick Borne Dis. 2012; 3:298-304.

-Espejo E, Andrés M, Garcia MC, Fajardo A, Pérez J, Bella F. Prospective Cohort Study of Single-Day Doxycycline Therapy for Mediterranean Spotted Fever. Antimicrob Agents Chemother. 2018; 62. pii: e00978-18.

-Anton E, Muñoz T, Travería FJ, Navarro G, Font B, Sanfeliu I, Segura F. Trial of Clarithromycin for Mediterranean Spotted Fever. Antimicrob Agents Chemother. 2015; 60:1642-5.

-Chomel B. Lyme disease. Rev Sci Tech. 2015; 34:569-76.

-Izac JR, Marconi RT. Diversity of the Lyme Disease Spirochetes and its Influence on Immune Responses to Infection and Vaccination. Vet Clin North Am Small Anim Pract. 2019. pii: S0195-5616(19)30037-3.

–Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS. Lyme borreliosis. Nat Rev Dis Primers. 2016; 2:16090.

–Halperin JJ. Neuroborreliosis. J Neurol. 2017; 264:1292-1297.

-Septfons A, Goronflot T, Jaulhac B, Roussel V, De Martino S, Guerreiro S, Launay T, Fournier L, De Valk H, Figoni J, Blanchon T, Couturier E. Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016. Euro Surveill. 2019; 24. doi: 10.2807/1560-7917.

-Geebelen L, Van Cauteren D, Devleesschauwer B, Moreels S, Tersago K, Van Oyen H, Speybroeck N, Lernout T. Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015-2017. Ticks Tick Borne Dis. 2019; 10:598-605.

-Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe. J Public Health (Oxf). 2017; 39:74-81.

-Rayment C, O’Flynn N. Diagnosis and management of patients with Lyme disease: NICE guideline. Br J Gen Pract. 2018; 68:546-547.

-Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme Disease – United States, 2008-2015. MMWR Surveill Summ. 2017; 66:1-12.

-Halperin JJ. Lyme neuroborreliosis. Curr Opin Infect Dis. 2019. doi: 10.1097.

-Webber BJ, Burganowski RP, Colton L, Escobar JD, Pathak SR, Gambino-Shirley KJ. Lyme disease overdiagnosis in a large healthcare system: a population-based, retrospective study. Clin Microbiol Infect. 2019. pii: S1198-743X(19)30086-2.

-Bušová A, Dorko E, Rimárová K, Diabelková J, Rovenská T, Feketeová E, Bereš M, Čellár R, Baranová Z, Kampe T, Benhatchi K. Seroprevalence of Lyme disease in Eastern Slovakia. Cent Eur J Public Health. 2018; 26 Suppl:S67-S71.

-Clark KL, Leydet B, Hartman S. Lyme borreliosis in human patients in Florida and Georgia, USA. Int J Med Sci. 2013; 10:915-31.

–No authors listed. Treatment of Lyme disease. Med Lett Drugs Ther. 2016; 58:57-8.

-Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin North Am. 2015; 29:309-23.